Company Profile
BMYBristol-Myers Squibb Company Stock Price, News & Analysis
- Ticker:
- BMY
- Exchange:
- NYSE
- Sector:
- Biopharmaceuticals
- Location:
- Princeton, New Jersey
Why the stock is moving
BMY is moving more like a steady commercial biopharma name than a stock in a sharp repricing phase. Its mature commercial base and diversified therapeutic exposure smooth volatility while the market waits for the next earnings or pipeline update.
Company overview
Business overview
Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease. The market watches the stock for commercial durability, pipeline replacement, and the pace at which new assets offset lifecycle pressure.
Geographic Base and Sector Classification
Headquartered in Princeton, New Jersey and listed on NYSE, Bristol Myers Squibb is followed within the large-cap biopharmaceutical universe for its global commercial footprint and broad therapeutic exposure.
Business Model Characteristics
Bristol Myers Squibb combines commercial cash flow with pipeline renewal and business-development decisions. Earnings, launch execution, and data releases matter because they help the market judge whether the franchise can keep evolving after older products mature.
Position Within the Biotechnology Landscape
Compared with clinical-stage peers, Bristol Myers Squibb trades more like a mature commercial biopharma platform, where pipeline progress matters but balance-sheet support and portfolio durability also shape the story.
Future catalysts
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does BMYBristol-Myers Squibb Company do?
Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease. The market watches the stock for commercial durability, pipeline replacement, and the pace at which new assets offset lifecycle pressure.
Where is BMYBristol-Myers Squibb Company based and where is the stock listed?
BMYBristol-Myers Squibb Company is listed on NYSE, Headquartered in Princeton, New Jersey and listed on NYSE, Bristol Myers Squibb is followed within the large-cap biopharmaceutical universe for its global commercial footprint and broad therapeutic exposure., followed in 肿瘤免疫治疗.
On which exchange is BMY stock listed?
BMYBristol-Myers Squibb Company (BMY) is associated with NYSE, Princeton, New Jersey, Biopharmaceuticals.
What is SUCCESSOR-2?
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout.
Which conditions is BMYBristol-Myers Squibb Company targeting with SUCCESSOR-2?
BMYBristol-Myers Squibb Company is associated with oncology, immunology, cardiovascular disease based on its company overview and current catalyst commentary.
How does BMYBristol-Myers Squibb Company describe recent progress with SUCCESSOR-2?
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout.
What is Bristol?
Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease.
What should investors watch for with Bristol?
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout.
What is Myers?
Bristol Myers Squibb is a large-cap biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular disease.